SCHEMBL4328263

SCHEMBL4328263

Fc1ccc(-c2cc(-c3cncc(F)c3)no2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 3/20 0.55
CXCR1 P25024 2/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2D6 P10635 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
NPC1 O15118 7/20 0.47
RAB9A P51151 7/20 0.47
ASIC1 P78348 1/20 0.47
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
CYP1A2 P05177 2/20 0.42
TDP1 Q9NUW8 1/20 0.41
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40
MAOB P27338 1/20 0.40
RET P07949 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4319858 0.91 PTGS2 (0.46) PTGS2CXCR1CYP3A4CYP2D6CYP2C9
SCHEMBL4318536 0.89 NPC1 (0.59) PTGS2CXCR1CYP3A4CYP2D6CYP2C9
SCHEMBL4321601 0.89 NPC1 (0.64) PTGS2CXCR1CYP3A4CYP2D6CYP2C9
SCHEMBL4322370 0.87 NPC1 (0.42) PTGS2CXCR1CYP3A4CYP2D6CYP2C9
SCHEMBL4319819 0.86 RAB9A (0.51) PTGS2CXCR1CYP3A4CYP2D6CYP2C9
SCHEMBL4326997 0.86 CYP3A4 (0.50) PTGS2CXCR1CYP3A4CYP2D6CYP2C9
SCHEMBL4315853 0.85 PTGS2 (0.56) PTGS2CXCR1CYP3A4CYP2D6CYP2C9
SCHEMBL4329664 0.84 CYP1A2 (0.54) PTGS2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4315758 0.84 NOTUM (0.43) PTGS2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4333333 0.83 CYP2C19 (0.53) CYP3A4CYP2D6CYP2C9CYP2C19NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383658-B2 Isoxazole based neuronal nicotinic receptor ligands and methods of use ABBOTT LABORATORIES (US) 2013-02-26 US claimed
WO-2009149135-A1 BIS (HETERO ) ARYL SUBSTITUTED ISOXAZOLES FOR USE AS NEURONAL NICOTINIC RECEPTOR MODULATORS ABBOTT LABORATORIES (US) 2009-12-10 WO claimed
US-20090306096-A1 Novel Isoxazoles and Methods of Use Thereof ABBOTT LABORATORIES (US) 2009-12-10 US claimed
US-8383658-B2 Isoxazole based neuronal nicotinic receptor ligands and methods of use ABBOTT LABORATORIES (US) 2013-02-26 US disclosed
WO-2009149135-A1 BIS (HETERO ) ARYL SUBSTITUTED ISOXAZOLES FOR USE AS NEURONAL NICOTINIC RECEPTOR MODULATORS ABBOTT LABORATORIES (US) 2009-12-10 WO disclosed
US-20090306096-A1 Novel Isoxazoles and Methods of Use Thereof ABBOTT LABORATORIES (US) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306096-A1 Novel Isoxazoles and Methods of Use Thereof XDH, PRDX5, CYP4X1 PTGS2 721/4885CXCR1 1286/4885CYP3A4 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.